Last reviewed · How we verify

Olumacostat Glasaretil Gel, 7.5%

Dermira, Inc. · Phase 1 active Small molecule

Olumacostat Glasaretil Gel, 7.5% is a Small molecule drug developed by Dermira, Inc.. It is currently in Phase 1 development. Also known as: DRM01.

At a glance

Generic nameOlumacostat Glasaretil Gel, 7.5%
Also known asDRM01
SponsorDermira, Inc.
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Olumacostat Glasaretil Gel, 7.5%

What is Olumacostat Glasaretil Gel, 7.5%?

Olumacostat Glasaretil Gel, 7.5% is a Small molecule drug developed by Dermira, Inc..

Who makes Olumacostat Glasaretil Gel, 7.5%?

Olumacostat Glasaretil Gel, 7.5% is developed by Dermira, Inc. (see full Dermira, Inc. pipeline at /company/dermira-inc).

Is Olumacostat Glasaretil Gel, 7.5% also known as anything else?

Olumacostat Glasaretil Gel, 7.5% is also known as DRM01.

What development phase is Olumacostat Glasaretil Gel, 7.5% in?

Olumacostat Glasaretil Gel, 7.5% is in Phase 1.

Related